Acute ischemic stroke therapy

European Neurology

Volumn 38, Issue 3, 1997, Pages 141-154

  Önal, Mehmet Ziilkiif ^a   Fisherb, Marc ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Acute ischemic stoke; Neuroprotective therapy; Thrombolytic therapy

Indexed keywords

1 METHYL 1,2 DIPHENYLETHYLAMINE; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ACETYLSALICYLIC ACID; ANTIOXIDANT; APTIGANEL; BASIC FIBROBLAST GROWTH FACTOR; BAY 3702; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; CLOMETHIAZOLE; DARODIPINE; DEXTRORPHAN; DIZOCILPINE; ELIPRODIL; FIBRINOLYTIC AGENT; FLUNARIZINE; GAVESTINEL; ION CHANNEL; ISRADIPINE; LIFARIZINE; LUBELUZOLE; NIMODIPINE; PHENYTOIN; PLASMINOGEN ACTIVATOR; PROPENTOFYLLINE; SIPATRIGINE; STREPTOKINASE; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGRAPHY; ARTICLE; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROPROTECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ACUTE DISEASE; BRAIN ISCHEMIA; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICAL SCAVENGERS; HUMANS; NEUROPROTECTIVE AGENTS; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0030882803     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113368     Document Type: Article

References (156)

1. Fisher M, Bogousslavsky J: Evolving toward effective therapy for acute ischemic stroke. JAMA 1993:270:360-364.
2. Silver B, Weber J, Fisher M: Review; medical thrapy for ischemic stroke. Clin Ncuropharma-col 1996:19:101-128.
3. Fisher M, Prichard JW, Warach S: New magnetic resonance techniques for acute ischemic stroke. JAMA 1995;74:908-911.
4. Mcldrum BS: Cytoprotective therapies in stroke. Curr Opin Neurol 1995:8:15-23.
5. Marder VJ, Sherry S: Thrombolytic therapy: Current status. Engl J Med 1988:318:1512-1585.
6. Verstracte M: Biochemical and clinical aspects of thrombolysis. Semin Hemalol 1978; 15:35.
7. Marder VJ: Thrombolytic therapy: Overview of results in major vascular occlusions. Thromb Haemost 1995;74:101-105.
8. Lijncn HR, Collen D: Fibrinolytic agents: Mechanisms of activity and pharmacology. Thromb Haemost 1995:74:387-390.
9. Mori E: Fibrinolytic recanalization therapy in acute cerebrovascular thromboembolism: in Hacke W, del Zoppo GJ. Hirschberg M (cds): Thrombolytic Therapy in Acute Ischemic Stroke. Berlin, Springer, 1991, pp 137-146.
10. Siesjo BK: Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J Neurosurg 1992:77: 337-354.
11. Macabasco AC, Hickman JL: Thrombolytic therapy for brain attack. J Ncurosci Nurs 1995; 27:138-149.
12. del Zoppo GJ, Hamann G, Fitridge R, Okada Y: Thrombolytic therapy: in Fisher M (eds): Stroke Therapy. Boston. Butterworth-Heine-mann. 1995, pp 291-313.
13. del Zoppo GJ: Acute stroke on the threshold of a therapy? N Engl J Med 1995:333:1632-1633.
14. Overgaard K: Thrombolytic therapy in experimental embolic stroke. Ccrcbrovasc Brain Me-tab Rev 1994:6:257-286.
15. Fisher M, Takano K: The penumbra, therapeutic time window and acute ischaemic stroke. Bailliére Clin Neurol 1995:4:279-295.
16. Wright RH, Ames A: Measurement of maximal permissable cerebral ischemia and a study of its pharmacological prolongation. J Neurosurg 1964;7:112-117.
17. Trembly B: Clinical potential for the use of neuroprotective agents; a brief overview. Ann NY Acad Sci 1995:765:1-20.
18. Scheinbcrg P: Stroke: the way things really are. Stroke 1994:25:1290-1294.
19. Brott TG, Haley EC, Levy DE Jr: Urgent therapy for stroke. Part I. Pilot study of tissue PA administered within 90 ms. Stroke 1992:23: 632-640.
20. Multiccnter Acute Stroke Trial-Italy (MAST-I) group: Randomized controlled trial of SK, aspirin and combination of both in treatment of acute ischemic stroke. Lancet 1995:346:1509-1514.
21. Hommel M, Boissel JP, Cornu C for the MAST study group: Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995:345:57.
22. Donnan GA, Hommel M, Davis SM, McNeill JJ for the steering committees of the ASK and M AST-E trials: Streptokinase in acute ischemic stroke. Lancet 1995:346:56.
23. Donnan GA, Davis SM, Chambers BR: Trials of streptokinase in severe acute ischemic stroke. Lancet 1995:345:578-579.
24. The Multicenter Acute Stroke Trial-Europe Study Group: Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996:335:145-150.
25. Hacke W, Kaste M, Fieschi C: Intravenous thrombolysis with recombinant tissue PA for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
26. Kaste M, Overgaard K, del Zoppo GJ for the ECASS study group: 21st Int Joint Conf Stroke Cerebral Circulation (abstract). Stroke 1996; 27:164A.
27. Fisher M, Pessin MS, Furian AJ: ECASS: Lessons for future thrombolytic stroke trials (editorial). JAMA 1995;274:1058-1059.
28. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue PA for acute ischemic stroke. N Engl J Med 1995:333:1581-1587.
29. Trouillas P, Nighoghossian N, Gctenet JC: Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data. Stroke 1996;27:882-890.
30. Mori E: Safety and efficacy of thrombolytic agents in acute ischemic stroke. Cerebrovasc Dis 1993:3:264-268.
31. del Zoppo GJ, Pessin MS, Mori E, Hacke W: Thrombolytic intervention in acute thrombotic and embolic stroke. Semin Neurol 1991; 11: 368-384.
32. del Zoppo GJ, Poeck K, Pessin MS: Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992:32:78-86.
33. von Kummer R, Forsting M, Hacke W, Sartor K: Recanalization, infarct volume, cerebral hemorrhage and clinical outcome after intravenous recombinant tissue plasminogen activator and heparin in acute carotid territory stroke: in del Zoppo GJ. Mori E. Hacke W (eds): Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin. Springer. 1993, pp 53-58.
34. Mori E, Yoncda Y, Tabuchi M: Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-982.
35. Yamaguchi T, Hayakawa T, Kikuchi H for the Japanese thrombolysis study group: Intravenous tissue plasminogen activator in acute thromboembolic stroke: A placebo controlled, double-blind trial: in del Zoppo GJ. Mori E, Hacke W (eds): Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin. Springer. 1993. pp 59-65.
36. Yamaguchi T, Kikuchi H, Hayakawa T: Clinical efficacy and safety of intravenous tissue: plasminogen activator in acute thromboembolic stroke: A randomized, double-blind, dose-comparison study of duteplase: Japanese thrombolysis study group: in Yamaguchi T. Mori E. Mincmatsu K. del Zoppo GJ (eds): Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo. Springer, 1995. pp 223-229.
37. Zcumer H, Freitag HJ, Grzyska U, Neunzig HP: Local intra-arterial fibrinolysis in acute vcrtcbrobasillar occlusion. Technical developments and recent results. Neuroradiology 1989; 31:336-340.
38. Ncsbit GM, Clark WM, O’Neill O, Barnwell SL: Intracranial intraarterial thrombolysis facilitated by microcatheter navigation through an occluded cervical internal carotid artery. J Neurosurg 1996:84:387-392.
39. del Zoppo G, Higashida RT, Furian A, Pessin MS, Gent M, Driscoll RM (Abott Laboratories) and the PROACT Investigators, The Scripps Research Institute; The Prolyse in Acute Cerebral Thromboembolism Trial (PROACT): Results of 6 mg dose tier (abstract). Stroke 1996: 27:164C.
40. Hacke W, Zeumer H, Ferbcrt A, Bruckmann H, del Zoppo GJ: Intra-arterial thrombolytic therapy improves outcome in patients with acute vcrtebro-basilar occlusive disease. Stroke 1988;19:1216-1222.
41. Ohtaki M, Shinya T, Yamamura A: Local fibrinolytic therapy using superselect ivc catheterization for patients with acute cerebral embolism within 10 hours; in Tomita M, Mchcdiish-vui G. Rosenblum W. Hciss WD. Fukuuchi Y (eds): Microcirculatory Stasis in the Brain. Amsterdam. Elsevier. 1993. pp 539-545.
42. Malsumoto K, Satoh K: Intra-arterial therapy in acute ischemic stroke: in Yamaguchi T, Mori E, Mincmatsu K, del Zoppo GJ (eds): Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo. Springer, 1995. pp 279-287.
43. Ezura M, Takahashi A, Yoshimoto T: Acute local fibrinolysis for embolic middle cerebral artery occlusion using recombinant tissue type plasminogen activator, in Yamaguchi T, Mori E, Mincmatsu K, del Zoppo GJ (eds): Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo. Springer. 1995, pp 335-338.
44. von Kummer R, Brandt T, Muller-Kuppers M, Hacke W, Sartor K: Thrombolytic therapy of basilar artery occlusion: Preconditions for recanalization and good clinical outcome: in Yamaguchi T. Mori E. Minematsu K. del Zoppo GJ (ed): Thrombolytic Therapy in Acute Ischemic stroke III. Tokyo, Springer, 1995. pp 343-348.
45. Higashida RT, Tsai FY, Halbach VV, Barnwell SL, Dowd CF, Hieshima GB: Interventional neurovascular techniques in the treatment of stroke, state-of-the-art therapy. J Intern Med 1995:237:105-115.
46. Sasaki O, Shigckazu T, Koike T, Koizumi T, Tanaka R: Fibrinolytic therapy for acute embolic stroke: Intravenous, intracarotid and intra-arterial local approaches. Neurosurgery 1995;36:246-253.
47. Ueda T, Hatakeyame T, Kumon Y, Sakaki S, Uraoka T: Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPF.CT. Stroke 1994;25:298-303.
48. Barr JD, Mathis JM, Wildenhain SL, Wechsler L, Jungreis CA, Horton JA: Acute stroke intervention with intra-arterial urokinase infusion. J Vase Intervent Radiol 1994:5:705-713.
49. Wildenhain SL, Jungreis CA, Barr JD, Mathis JM, Wechsler L. Horton JA: CT after intracranial thrombolysis for acute stroke. AJ NR 1994: 15:487-492.
50. Barrnwcll SL, Clark WM, Nguyen T, O’Neill O, Wvnn M, Coull B: Safety and efficacy of delayed intra-arterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR 1994; 15:1817-1822.
51. Jansen O, von Kummer R, Forsting M, Hacke W, Sartor K: Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation.AJNR 1995;16:1977-1986.
52. Brandt T, von Kummer R, Mullers-Kuppcrs M, Hacke W: Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996:27: 875-881.
53. Ferguson RD, Ferguson JG: Cerebral intra-arterial fibrinolysis at the crossroads: is aphase III '.rial advisable at this lime? AJNR 1994:15: 1201-1216.
54. Sasaki O, Takcuchi S, Koike T, Koizumi T, Tanak R: Fibrinolytic therapy for acute embolic stroke: Intravenous, intracarotid and intraarterial local approaches. Neurosurgery 1995;36:246-253.
55. Simoons ML, de Jacgere P, van Domburg R, Boersma E: Intracranial hemorrhage after thrombolytic therapy. A perspective. Z Kardiol 1982;2:153-156.
56. Adams HPJ, Brott TG, Furian AJ, Gomez CR, Grotta J, Ilelgason CM. Kwiatkowski T. Lydcn PD. Marier JT. Feinberg W, Maybcrg M.Thies W: Guidelines for thrombolytic therapy for acctc stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke 1996:27:1711-1718.
57. Kase CS, O'Neal AM, Fisher M, Girgis GN, Ordia J I: Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Inter Med 1990:112:17-21.
58. Okada Y, Yamaguchi T, Minematsu K: Hemorrhagic transformation in cerebral embolism. Stroke 1989:20:598-603.
59. Higashida RT, Halbach W, Dowd CF: Intra-vascular balloon dilation therapy for intracranial arterial vasospasm: Patient selection, technique and clinical results. Neurosurg Rev 1992; 15:89-95.
60. Chapman AB, Rubinstein D, Hughes R: Intracranial aneurysms in autosomal-dominant polycystic kidney disease. N Engl J Med 1992; 327:916-920.
61. Mori E, Yoncda Y, Ohksawa S: Double-blind, placebo controlled trial of a recombinant tissue plasminogen activator in acute carotid stroke (abstract). Neurology 1991;41 (suppl 1):347.
62. Ptlsinelli W: Pathophysiology of acute ischaemic stroke. Lancet 1992;339:533-536.
63. Choi D: Methods for antagonizing glutamate neurotoxicity. Cerebvasc Brain Mctab Rev 1990;2:105-147.
64. Ferger D, Krieglstein J: Cerebral ischemia: Pharmacological bases of drug therapy. Dementia 1996:7:161-168.
65. Rami A, Rabi A, Thomassel M, Krieglstein J: Calbindin-D;#K and ischemic damage of pyramidal cells in rat hipocampus. J Neurosci Res 1992:31:89-95.
66. van den Kerckhoff W, Drewcrs LR: Transfer of the Ca-antagonists nifedipine and nimodipine across the blood-brain barrier and their regional distribution in vivo. J Cereb Blood Flow Metab l985;suppl):459-460.
67. Mohr JP, Orgogozo JM, Harrison MJG: Mela-analvsis of oral nimodipine trials in acute ischemic stroke. Ccrcbrovasc Dis 1994;4:197-203.
68. Heiss WD, Holthoff V, Pawlik G, Nevcling M: Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischemic stroke as measured by positron emission tomography. J Cereb Blood Row Metab 1990; 10:127-132.
69. Norris JW, Lc Brun LH, Anderson BA (The Canwin Study Group): Intravenous nimodipine in acute ischemic stroke. Cercbrovasc Dis 1994;4:194-196.
70. Wahlgren NG, MacMahon DG, De Kevscr J, Indrcdavik B, Rvman T for the INWEST study group: Intravenous Nimcdipinc West European Stroke Trial of nimodipine in the treatment of acute ischemic stroke. Cercbrovasc Dis 1994;4:204-210.
71. Gelmers JH, Hennerichi M: Effect of nimodipine on acute ischemic stroke. Pooled results from five randomized trials. Stroke 1990; 21(suppl 4):81-84.
72. Vorstrup SA, Blegvad N, Paulson OB: Calcium antagonist (PY 108-068) treatment may further decrease flow in ischemic areas in acute stroke. J Cereb Blood How Metab 1986;6:222-229.
73. Oczkowski WJ, Hachinski VC, Bogousslavsky J, Barnett HJM, Carruthers SG: A doubleblind. randomized trial of PY 108-068 in acute ischemic cerebral infarction. Stroke 1989:20: 604-608.
74. Azcona A, Lataste X: Isradipine in patients with acute ischemic cerebral infarction; an overview of the ASCLEPIOS programme. Drugs 1990;40(supp1 2):52-57.
75. Lataste X, Maurer W. Whitehead J and the ASCLEPIOS study group: Application of sequential methods to clinical trial in stroke: The Asclcpios Study. 2nd World Congr Stroke, Washington. D.C. 1992. p 16.
76. Limburg M, Hijdra A: Flunarizine in acute ischemic stroke: A pilot study. Eur Neurol 1990;30:121-122.
77. Prange H, Hargung J, Hertel G (the German Flunarizine Study Group): Treatment of acute stroke with flunarizine intravenous. Proc Int Conf Stroke. Geneva. 1991, p 39.
78. Muir KW, Lees KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-513.
79. The Anerod Stroke Study Investigators: An-crod for the treatment of acute brain infarction. Stroke 1994;25:1755-1759.
80. Wahlgren NG: Cytoprotcctive therapy for acute ischemic stroke: in Fisher M (ed): Stroke Therapy. Boston. Buttcrworth-Heinemann. 1995. pp 315-350.
81. Sills MA, Loo PS: Tricyclic antidcpressants and dextromethorphan bind w ith higher affinity to the phencycline receptor in the absence of magnesium and L-glutamatc. Mol Pharmacol 1989;36:160-165.
82. Buchan AM, Lesiuk H, Barnes KA, Li H, Smith KE, Xue D: AMPA antagonists: Do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke I993:24(suppl 1): 148-152.
83. Koek W, Woods JH, Winger GD: MK-801. a proposed noncompetitive antagonist of excitatory amino acid transmission produces phencyclidine-like behavioral effect in pigeons, rats and rhesus monkeys. J Pharmacol Exp Thcr 1988:245:969-974.
84. Park CK, Nehls DG, Teasdale GM, McCuIIoch J: Effect of the NMDA antagonist MK-801 on the local cerebral blood flow in focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1989:9:617-622.
85. Wong EH, Kemp JA, Priestly T, Knight AR, Woodruff GN, Iversen LL: The anticonvulsant MK-801 is a potent N-mcthyl-D-asparate antagonist. Proc Natl Acad Sci USA 1986:83: 7104-7108.
86. Albers GW, Saenz RE, Moses JA, Choi DW: Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemic stroke. Stroke 1991:22:1075-1077.
87. Albers GW, Atkinson RP, Kelley RE. Rosenbaum MD on behalf of the Dcxtrorphan Study Group: Safety, tolcrability and pharmacokinetics of the N-mcthyl-D-aspartatc antagonist dextrorphan in patients with acute stroke. Stroke 1995:26:254-258.
88. Albers GW, Atkinson RP, Kelley RE for The Dextromethorphan Study Group and Hoff-mann-La Roche: Safety, tolcrability and pharmacokinetics of the N-mcthyl-D-aspartate antagonist Ro-01-6794/706 in patients with acute ischemic stroke. Ann NY Acad Sci 1995:765: 249-261.
89. Fisher M for CNS 1102-003 Investigators: Cerestat (CNS 1102), a non-competitive NMDA antagonist in ischemic stroke patients: Dose escalating safety study. Ccrebrovasc Dis 1994:4:245.
90. Edwards K and the CNS 1102-008 Study Group: Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: Results of phase II trial. AAN Meetings: S62.002. Neurology 1996;46:(suppl 1):A424.
91. Muir KW, Lees KR: Initial experience with rcmaecmide hydrochloride in patients with acute ischemic stroke (abstract). Proc 2nd Int Conf Neuroprotective Agents. Lake George. 1994.
92. Strand T, Wester PO: A double blind randomized pilot trial of magnesium therapy in acute cerebral infarction. 7th Nord Meet Ccrebrovasc Dis, 1993. p 37.
93. Muir KW, Lees KR: A randomized, doubleblind. placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Ann N YAcad Sci 1995:765:315-316.
94. Warkins JC, Olevcman HJ: Agonist and antagonists for excitatory aminoacid receptors. Trends Neurosci 1987:10:265-272.
95. Boast CA, Gerhardt SC, Pastor G: The N-mcthyl-D-aspartatc antagonists. CGS19755 and CPP reduce ischemic brain damage in gcr-bils. Brain Res 1988:442:395-398.
96. Hasegawa Y, Fisher M, Baron MB, Metcalf G: The competitive NMDA antagonist MDL 100.453 reduces infarct size after experimental stroke. Stroke 1994;25:1241-1246.
97. Grotta J for the CGS19755 Study Group: Safety and tolcrability of the glutamate antagonist CGS19755 in acute stroke patients. 19th Int Joint Conf Stroke Cereb Circulation. Stroke 1994:25:255.
98. Clark WM, Coull BM for the CGS 19755 Study Group: Randomized trial of CGS19755, a glutamate antagonist, in acute ischemic stroke. Stroke 1994:44(suppl 2): A270.
99. Coull BM: Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stroke treatment (abstract). American Academy of Neurology Annu Meet. Minneapolis. Minn. 1994.
100. Williams K, Romano C, Dichter MA, Moli-noff PB: Modulation of the NMDA receptor by polyamines. Life Sci 1991.48:469-498.
101. Fisher M: Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995:35:3-7.
102. Klcckner NW, Dingledine R: Requirements for glycine in activation of NMDA receptors expressed in Xcnopus oocytes. Sciences 1988; 241:835-837.
103. Tridgett R, Foster AC: Prevention of NMDA receptor-mediated ncurodegeneration in the rat striatum by an antagonist at the glycine modulatory site. Br J Pharmacol 1988:85: 890.
104. Warner DS, Martin H, Ludwig P: In vivo models of cerebral ischemia: Effects of paren-tcrally administered NMDA receptor glycine site antagonists. J Cereb Blood Row Metab 1995:15:188-196.
105. Graham SH, Chen J, Lan J, Leach MJ, Simon RP: Ncuroprotcctivc effect of a use dependent blocker of voltage dependent sodium channels. BW619C89. in rat MCA occlusion. J Pharmacol ExpTher 1994:269:854-859.
106. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs. BW619C89. a glutamate release inhibitor. protects against focal cerebral ischemic damage. Stroke 1993:24:1063-1067.
107. Smith SE, Lekieffre D, Sowinski P, Meldrutn BS: Cerebropratective effect of BW619C89 after focal or global cerebral ischemia in the rat. Neuroreport 1993:4:1339-1342.
108. Muir KW, Lees KR, Hamilton SJC, George CF, Hobbiger SF, Lunnon MW: A randomized. double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke. Ann NY Acad Sci 1995:765: 328-329.
109. Dunwiddie TV: The physiological role of adenosine in the central nervous system. Int RevNeurobiol 1985:27:63-139.
110. Fredholm BB, Dunwiddie TV: How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988;9:130-134.
111. I 11 Huber M, Kittner B, Hojer C, Fink GR, Nev-eling M, Heiss WD: Effect of propentophyl-line on regional cerebral glucose metabolism in acute ischemic stroke. J Cereb Blood Row Metab 1993:13:526-530.
112. Tietjen GE, Dombi T, Pulsinelli WA, Becske T, Kugler AR, Mann ME: A double-blind, safety and tolerance study of single intravenous doses of fosphenytoin in patients with acute ischemic stroke. AAN Meetings: S62.003. Neurology 1996;46(suppl 1):A424.
113. Scheller D, Kolb J, Szathmary S: Extracellular changes of glutamate in the peri-infarct zone: Effect of lubeluzolc. J Ccrcb Blood Flow Me-tab 1995:15(suppl 1):S379.
114. Lcsagc AS, de Loorc KL, Osikowska-Evcrs B, Peeters L, Leysen JF: Lubcluzole. a novel neuroprotectant, inhibits the glutamate activated NOS pathway. Soc Neurosci Abstr 1994, 20:185.
115. Diener HC, Hacke W, Henncrichi M, Rad-berg J, Hantson L, de Keyser J for the Lubelu-zole International Study Group: Lubcluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial. Stroke 1996:27: 76-81.
116. Squire IB, Lees KR, Pryse-Phillips W, Ker-tcsz A, Bamford J for the Lifarizine Study Group: Efficacy and tolerability of liferazinc in acute ischemic stroke. A pilot studv. Ann N Y Acad Sei 1995:765:317-318.
117. Keinanen K, Wisden W, Sommer B: A family of AMPA-selective glutamate receptors. Science 1990;299:556-560.
118. Choi DW. Koh J. Peters S: Pharmacology of glutamate neurotoxicity in cortical cell culture: Attenuation by NMDA antagonists. J Neurosci 1988;8:185-196.
119. Koh J, Goldberg MP, Hartley DM, Choi DW: Non-NMDA receptor-mediated neurotoxicity in cortical culture. J Neurosci 1990:10: 693-705.
120. Meden P, Overgaard K, Sereghy T, Boysen G: Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model. J Neurol Sei 1993:119: 209-216.
121. Nurse S, Corbett D: Neuroprotection after several days of mild, drug-induced hypothermia. J Cercb Blood Flow Metab 1996:16: 474-480.
122. Bielenberg GW, Burkhardt M: 5-hydroxy-tryptaminetA agonists; a new therapeutic principle for stroke treatment. Stroke 1990: 21 (supp1 4): 161-63.
123. Bode-Greuel KM, Klisch J, Horvath E, Glaser T, Traber J: Effects of 5-hydroxytrypta-mineiA-reccptor agonists on hipocampal damage after transient forebrain ischemia in the Mongolian gerbil. Stroke 1990:21 (suppl 4): 164-166.
124. Fagg GE, Foster AC: Am ino acid neurotrans-mittersand their pathways in the mammalian central nervous system. Neuroscience 1983; 96:701-719.
125. Barnard EA, Darlison MG, Fujita N: Molecular biology of GABA-A-receptor. Adv Exp Med Biol 1988:236:31-45.
126. Green AR, Cross AJ, Snape MF, de Souza RJ: The immediate consequences of MCA occlusion on GABA synthesis in mouse cortex and cerebellum. Neurosci Lett 1992; 138:141-144.
127. Shuaib A, Mazagri R, Ijaz S: GABA agonist muscimol is ncuroprotectivc in repetitive transient forebrain ischemia in gerbils. Exp Neurol 1993;123:284-288.
128. Snape MF, Baldwin HA, Cross AJ, Green AR: The effects of chlormcthizoale and ni-modipine on cortical infarct area after focal cerebral ischemia in the rat. Neuroscience 1993;53:837-844.
129. Carolei A, Fieschi C, Bruno R, TolTano G: Monoganglioside GMI in cerebral ischemia. Ccrebvasc Brain Metab Rev 1991:3:134-157.
130. The SASS investigators: GangliosidcGM-1 in acute ischemic stroke. Stroke 1994:25:1141-1148.
131. Scheinbcrg P: The biologic basis for the treatment of acute stroke. Neurology 1991;41: 1867-1873.
132. Lenzi GL, Grigoletto F, Gent M, the Early Stroke Group: Early treatment of stroke with monosialoganglioside GM-1. Stroke 1994:25: 1552-1558.
133. Sicsjo BK, Agardh CD, Bengtsson F: Free radicals and brain damage. Ccrebvasc Brain Metab Rev 1989:1:165-211.
134. Flamm ES, Demopoulos HB, Scligman ML, Poser RG, Ransohoff J: Free radicals in cerebral ischemia. Stroke 1978;9:445-447.
135. STIPAS investigators: Safety study of lirizi-lad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994:25:418-423.
136. The RANTTAS Investigators: A Randomized trial of Tirilazad Mesylate in patients with acute stroke (RANTTAS). Stroke. 1996; 27:1453-1458.
137. Garcia JH, Liu KF, Relton JK: Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with MCA occlusion. Am J Path 1995:147:1477-1486.
138. Garcia JH, Liu KF, Bree MP: Effects of CD1 lb/18 monoclonal antibody on rats with permanent middle cerebral occlusion. Am J Path 1996;148:241-248.
139. Jiang N, Moyle M, Soule H, Rote W, Chopp M: Neutrophil inhibitory factor is neuropro-tectivc after focal ischemia in rats. Ann Ncur 1995;148:241-248.
140. Polmar SH, Sherman DG: Double-blind, randomized, placebo-controlled trial of the efficacy and safely of enlimomab (anti-ICAM-1) compared to placebo administered within 6 hours of the onset of stroke symptoms, for treatment of acute ischemic stroke. 21st Int Joint Conf Stroke Ccrcb Circulation. Stroke 1996:27:177.
141. D'Orlando KJ, Sandage BW Jr: Citicoline (CDP-cholinc): mechanisms of action and effects in ischemic brain injury. Neurol Res 1995;17:281-284.
142. Clark WM, Portland OR, Warach SJ for the Citicoline Study Group: Randomized dose response trial of citicoline in acute ischemic stroke patients. AAN Meetings: S62.004. Neurology 1996;46(suppl 1):A425.
143. Fisher M, Meadows ME, Do T, Weise J, Trubetskoy V, Charettc M, Finkelstein SP: Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J Ccreb Blood How Metab 1995; 15:953-959.
144. Gross CE, Bednar MM, Howard DB, Spom MB: Transforming growth factor-Bl reduces infarct size after experimental cerebral ischemia in a rabbit model. Stroke 1993:24:558-562.
145. Dorman PJ, Sandercock AG: Considerations in the design of clinical trials of neuroprotec-tive therapy in acute stroke. Stroke 1996;27: 1507-1515.
146. Saunders DE, Howe FA, van der Boogaait A, McCIean MA, Griffiths JR, Brown MM: Continuing ischemic damage after acute middle cerebral artery infarction in humans demonstrated by short-echo proton spectroscopy. Stroke 1995;26:1007-1013.
147. Charriaut-Marlanguc C, Margaill I, Reprcsa A, Popovici T, Plotkinc M, Ben-Ari Y: Apop-tosis and necrosis after reversible focal ischemia: An in situ DNA fragmentation. J Cereb Blood How Metab 1996;16:186-194.
148. Matsushima K, Schmidt-Kastncr R, Hakim AM: Genes and cerebral ischemia: Therapeutic perspectives. Cerebrovasc Dis 1996:6: 119-127.
149. Heistad DD, Farachi FM: Gene therapy for cerebrovascular disease. Stroke 1996:27: 1688-1693.
150. Practice Advisory: Thrombolytic therapy for acute ischemic stroke - Summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;47:835-839.
151. Donnan GA, Davis SM, Chambers BR, Gatss PC, Hankey GJ, McNeil JJ, Rosen D, Ste-ward-Wynne EG, Tuck RR; for the Australian Streptokinase Trial (ASK) Study Group: Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-966.
152. Sereghy T, Overgaard N, Boysen G: Neuro-protection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 1993:24:1702-1708.
153. Zivin JA, Mazzarella V: Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991:48:1235-1238.
154. Uematsu D, Araki N, Greenberg JH: Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage. Neurology 1991:41:88-94.
155. Lyden PD, Lonzo L: Combination therapy protects ischemic brain in rats. A glutamate antagonist plus a y-aminobutyric acid agonist. Stroke 1994;25:189-196.
156. 5nal MZ, Li F, Tathsumak T, Locke KW, Sandage BW, Fischer M: Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats. Stroke 1997; 28(5): 1060-1065.